Cancer immunotherapies targeting the PD-1 signaling pathway

Journal of Biomedical Science

Review

Junzo Hamanishi¹  Kenji Chamoto²  Tasuku Honjo²  Yoshiko Iwai³ 

[1] Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan;Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, 606-8501, Kyoto, Japan;Department of Molecular Biology, School of Medicine, University of Occupational and Environmental Health Japan, 807-8555, Kitakyushu-shi, Fukuoka, Japan;

关键词: PD-1;    PD-L1;    Cancer immunotherapy;    Immune checkpoint;   

DOI  :  10.1186/s12929-017-0329-9

 received in 2017-03-10, accepted in 2017-03-20,  发布年份 2017

来源: Springer

【 摘 要 】

Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.

【 授权许可】

CC BY   
© The Author(s). 2017